David Garcia: Steering Committee: Bristol Myer Squibb. Advisory board: Daiichi Sankyo, Boehringer Ingelheim, Bristol Myer Squibb and CSL Behring. Eliabeth Van Cott: Nothing to report. Peter Kouides: Physician advisory board: CSL Behring. Consultant: Baxter and Ferring.
Introductory remarks for the THSNA meeting proceedings: Hemostasis and thrombosis at the cutting edge†
Version of Record online: 4 APR 2012
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 87, Issue S1, page S1, May 2012
How to Cite
Garcia, D., Van Cott, E. M. and Kouides, P. A. (2012), Introductory remarks for the THSNA meeting proceedings: Hemostasis and thrombosis at the cutting edge. Am. J. Hematol., 87: S1. doi: 10.1002/ajh.23181
- Issue online: 19 APR 2012
- Version of Record online: 4 APR 2012
- Accepted manuscript online: 12 MAR 2012 05:06AM EST
- Manuscript Accepted: 27 FEB 2012
- Manuscript Received: 24 FEB 2012
We are very fortunate that in North America there are numerous organizations in the hematology subdiscipline of hemostasis and thrombosis that hold an annual meeting. These meetings provide an excellent educational content with varying emphasis on cutting edge research in the field of hemostasis and thrombosis. Although each of these meetings individually has great value, many members of our respective groups have felt that the organizations could unite to form an even stronger, multidisciplinary international North American “super-meeting” dedicated to hemostasis and thrombosis. The Thrombosis and Hemostasis Summit of North America (“THSNA”), held May 3–5, 2012 in Chicago, IL, represents the efforts of nine collaborating organizations to create a single gathering where individuals with an interest in hemostasis and/or thrombosis could find both an unparalleled opportunity to network with colleagues as well as a superb educational and scientific program.
The present supplement of the American Journal of Hematology contains the content of the educational sessions and the abstracts of this meeting. In addition, the supplement includes a consensus statement, developed by a group of members from all THSNA member organizations, that addresses the management of bleeding associated with new oral anticoagulants. The reader will soon discover the multidisciplinary nature of hemostasis and thrombosis; the care of (and research pertinent to) patients with these disorders includes hematologists, nurses, pharmacists, pediatricians, internists, laboratory physicians, and technologists, interventionalists, obstetrician and gynecologists, and basic scientists. We hope that these proceedings from the inaugural “THSNA” will help clinicians apply evidence-based care to their patients and inspire investigators to address unanswered questions in our field.
Members of THSNA are Association of Hemophilia Clinic Directors of Canada (AHCDC), Anticoagulation Forum (AC Forum), American Thrombosis and Hemostasis Network (ATHN), Foundation for Women and Girls with Blood Disorders (FWGBD), Hemostasis and Thrombosis Research Society (HTRS), National Blood Clot Alliance (NBCA), National Hemophilia Foundation (NHF), North American Specialized Coagulation Laboratory Association (NASCOLA), and Thrombosis Interest Group of Canada (TIGC).